The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > ORGANIZATION
ORGANIZATION
- JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
December 9, 2013
- Survey Finds that 1 in 4 MRs Still Smoke; Board Member of JSTC Calls Finding “Extremely Disappointing”
November 15, 2013
- JPA Express Deep Regrets over Decision on Lifting Online Sales Ban of OTC Drugs
November 11, 2013
- Mr Shirakawa of Kenporen Calls for New Look at Range of Drugs Eligible for Premium for New Drug Development
November 11, 2013
- Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
- JPMA Issues “Severe Warning” to MTPC for Violation of PAL Related to Medway Injection
November 1, 2013
- PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
- Keizai Doyukai Recommends Measures to Ensure Adequate Funding for Proposed Japanese NIH
October 31, 2013
- Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
- Medwatcher Japan Calls for Legislation to Regulate Clinical Research in Wake of Diovan Scandal
October 28, 2013
- JPMA to Consider Information Disclosure on Provision of Labor to Research Institutes in Response to Diovan Scandal
October 28, 2013
- JMA Vice Pres. Nakagawa to Be Reinstated as CSIMC Member
October 25, 2013
- No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…